[ad_1]
Reuters
The founders of the company “Biontech” confirmed that the company was working at full capacity with its partner, “Pfizer”, to increase production of their vaccine against Covid-19, but they warned of the possibility of disruption of the ‘vaccine supply until more vaccines are launched.
Biontec was the first in Germany in the vaccine race, but its vaccine is slowly arriving in the European Union due to the relatively late approval of the vaccine by the European Union health authority and weak demand from Brussels .
Delays in launching the vaccine caused panic in Germany, as some regions were forced to stop vaccination a few days after it started.
Read more
“At the moment, things don’t look good, and a gap is emerging as there is a shortage of other licensed vaccines and we have to fill the need for our own vaccine,” Biontec CEO Ugur Shaheen said in statements to the weekly newspaper Spiegel.
The United States ordered 600 million doses of the “Pfizer-Biontech” vaccine in July, while the European Union waited until November to place an order for half that amount.
Source: “Reuters”
[ad_2]
Source link
